Clinical decision support analysis of a microRNA-based thyroid molecular classifier: A real-world, prospective and multicentre validation study

Autor(es):Mostrar menos -

Santos, Marcos Tadeu ; Rodrigues, Bruna Moretto ; Shizukuda, Satye ; Oliverira, Andrei Felix ; Oliveira, Miriane ; Figueiredo, David Livingstone Alves ; Melo, Giulianno Molina ; Silva, Rubens Adao ; Fainstein, Claudio ; dos Reis, Gerson Felisbino ; Corbo, Rossana ; Ramos, Helton Estrela ; Camacho, Cleber Pinto ; Vaisman, Fernanda ; Vaisman, Mario

• Tipo de documento: Artigo Científico
• Fonte: EBIOMEDICINE; v. 82, p. 9-pg., 2022-07-01.

Resumo

Background The diagnosis of cancer in Bethesda III/IV thyroid nodules is challenging as fine-needle aspiration (FNA) has limitations, and these cases usually require diagnostic surgery. As approximately 77% of these nodules are not malignant, a diagnostic test accurately identifying benign thyroid nodules can reduce "potentially unnecessary " surgery rates. We have previously reported the development and validation of a microRNA-based thyroid classifier (mir-THYpe) with high sensitivity and specificity, which could be performed directly from FNA smear slides. We sought to evaluate the performance of this test in real-world clinical routine to support clinical decisions and to reduce surgery rates. Methods We designed a real-world, prospective, multicentre study. Molecular tests were performed with FNA samples prepared at 128 cytopathology laboratories. Patients were followed-up from March 2018 until surgery or until March 2020 (patients with no indication for surgery). The final diagnosis of thyroid tissue samples was retrieved from postsurgical anatomopathological reports. Findings A total of 435 patients (440 nodules) classified as Bethesda III/IV were followed-up. The rate of avoided surgeries was 52.5% for all surgeries and 74.6% for "potentially unnecessary " surgeries. The test achieved 89.3% sensitivity, 81.65% specificity, 66.2% positive predictive value, and 95% negative predictive value. The test supported 92.3% of clinical decisions. Interpretation The reported data demonstrate that the use of the microRNA-based classifier in the real-world can reduce the rate of thyroid surgeries with robust performance and support clinical decision-making. (AU)

• Processo FAPESP: 17/16417-9 - Caracterização e validação multicêntrica de um exame molecular para classificação de nódulos tireoidianos indeterminados baseado em microRNA profiling
• Beneficiário: Marcos Tadeu dos Santos
• Modalidade de apoio: Auxílio à Pesquisa - Pesquisa Inovativa em Pequenas Empresas - PIPE
• Processo FAPESP: 21/06579-7 - Validação em novas indicações clínicas, otimizações e ampliação de acesso e inserção no mercado do exame mir-THYpe®, classificador molecular de nódulos tireoidianos indeterminados baseado em microRNA profiling
• Beneficiário: Marcos Tadeu dos Santos
• Modalidade de apoio: Auxílio à Pesquisa - Pesquisa Inovativa em Pequenas Empresas - PIPE